Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11-Reference-Cited by-同舟云学术

Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11

Published:2011-01 Issue:1 Volume:81 Page:24-31
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Hatfield M. Jason,Tsurkan Lyudmila,Garrett Michael,Shaver Timothy M.,Hyatt Janice L.,Edwards Carol C.,Hicks Latorya D.,Potter Philip M.

Funder

NIH

American Lebanese Syrian Associated Charities

St. Jude Children's Research Hospital (SJCRH)

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference27 articles.

1. Comparison of topoisomerase I inhibition DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials;Tanizawa;J Natl Cancer Inst,1994

2. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy;Danks;Clin Cancer Res,1999

3. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11;Danks;Cancer Res,1998

4. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2;Humerickhouse;Cancer Res,2000

5. Proficient metabolism of CPT-11 by a human intestinal carboxylesterase;Khanna;Cancer Res,2000

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Deoxynivalenol and Its Acetylated Derivatives on Lipid Metabolism in Human Normal Hepatocytes;Toxins;2024-06-26

2. In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition;Drug Metabolism and Pharmacokinetics;2024-06

3. Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer;Technology in Cancer Research & Treatment;2024-01

4. Drug and pro-drug substrates and pseudo-substrates of human butyrylcholinesterase;Biochemical Pharmacology;2023-12

5. Physiologically-Based Pharmacokinetic Modeling for Drugs Cleared by Non-Cytochrome P450 Enzymes: State-of-the-Art and Future Perspectives;Drug Metabolism and Disposition;2023-10-25